Company news

Ionis Pharmaceuticals, Inc. news in 2024

Ionis Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.

View company

TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet

December 18, 2024

Ionis reports third quarter 2024 financial results

November 5, 2024

Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome

November 5, 2024

Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE

November 3, 2024

Ionis to hold third quarter 2024 financial results webcast

October 22, 2024

WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis

October 20, 2024

New positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

October 2, 2024

Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease

September 30, 2024

Ionis announces proposed public offering of common stock

September 8, 2024

Ionis announces pricing of $500.3 million public offering

September 8, 2024

Ionis reports second quarter 2024 financial results

July 31, 2024

Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome

July 21, 2024

Ionis to hold second quarter 2024 financial results webcast

July 18, 2024

Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease

July 17, 2024

Ionis announces webcast to report HALOS study results for ION582 in Angelman syndrome

July 7, 2024

Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed

June 24, 2024

Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema

June 17, 2024

Ionis to present at TD Cowen Genetic Medicines & RNA Summit

June 16, 2024

Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema

May 30, 2024

Ionis to hold donidalorsen Phase 3 data webcast

May 27, 2024

New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™ (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA)

May 22, 2024

Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome

May 15, 2024

Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

May 15, 2024

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

May 15, 2024

Ionis to host 2024 virtual Annual Meeting of Stockholders

May 14, 2024

Ionis reports first quarter 2024 financial results

May 6, 2024

Ionis Publishes 2023 Corporate Responsibility Report

April 24, 2024

Ionis to hold first quarter 2024 financial results webcast

April 22, 2024

Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome

April 6, 2024

Ionis to hold olezarsen Phase 3 data webcast

March 27, 2024

Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting

March 24, 2024

Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH

March 12, 2024

Ionis announces new chief global product strategy officer to lead next phase of commercial growth

February 28, 2024

Ionis reports fourth quarter and full year 2023 financial results

February 20, 2024

Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome

February 14, 2024

Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy

February 7, 2024

Ionis to hold fourth quarter and full year 2023 financial results webcast

February 6, 2024

Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema

January 21, 2024

Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases

January 7, 2024

Calls in 2024

Decks in 2024